Justin Stebbing to Sulfonamides
This is a "connection" page, showing publications Justin Stebbing has written about Sulfonamides.
Connection Strength
2.902
-
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021 10; 69(10):2752-2758.
Score: 0.476
-
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Ann Rheum Dis. 2021 09; 80(9):1245-1246.
Score: 0.473
-
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021 01; 7(1).
Score: 0.459
-
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020 08 07; 12(8):e12697.
Score: 0.443
-
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 02 15; 395(10223):e30-e31.
Score: 0.431
-
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021 12; 9(12):1349-1351.
Score: 0.120
-
The Emergence of Baricitinib: A Story of Tortoises Versus Hares. Clin Infect Dis. 2021 04 08; 72(7):1251-1252.
Score: 0.117
-
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020 Nov; 19(11):1505-1511.
Score: 0.111
-
Baricitinib for COVID-19: a suitable treatment? - Authors' reply. Lancet Infect Dis. 2020 09; 20(9):1013-1014.
Score: 0.109
-
COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 04; 20(4):400-402.
Score: 0.108
-
Reply to letter to the editor: baricitinib and toxicity is a rare occurrence. Expert Opin Drug Saf. 2020 10; 19(10):1371-1372.
Score: 0.028
-
CNS penetration of potential anti-COVID-19 drugs. J Neurol. 2020 Jul; 267(7):1880-1882.
Score: 0.027